FMC 3Q 2026 Earnings Call - FMC CORP

Financial Performance:

• Q3 2026 revenue was $1.06 billion, including a $639 million negative impact from commercial actions; underlying sales were $745 million, missing the original guidance low end due to volume declines and pricing headwinds.
• Adjusted EBITDA was -$559 million, including a $672 million non-cash charge for commercial actions; underlying adjusted EBITDA was $113 million, below the low-end guidance.
• Adjusted EPS was -$4.41, significantly missing guidance primarily due to the commercial action charges.
• Free cash flow (FCF) for Q3 was -$18 million, improved by $214 million year-over-year due to working capital improvements offsetting lower EBITDA.
• Full-year 2026 FCF guidance was revised to -$350 million to -$150 million, driven by lower Q3/Q4 EBITDA, reduced Q4 collections, and increased restructuring spending.
• Q3 net debt decreased $48 million to $3.4 billion following a $403 million equity investment from Tessenderlo Group, resulting in a secured debt-to-covenant EBITDA ratio of 1.4x and interest coverage of 2.3x.
• Full-year 2026 interest expense is expected to be $270–$280 million, and depreciation/amortization is expected to be $160–$170 million.
• Effective tax rate on adjusted earnings for 2026 is projected at 12–14%, reflecting a reduction from previous estimates due to negative reported earnings.

Guidance and Future Outlook:

• Q4 2026 revenue guidance is $1.04–$1.14 billion (flat to prior year midpoint), with EBITDA of $210–$230 million (down 22% YoY) and EPS of $0.56–$0.70.
• Preliminary outlook for 2027 adjusted EBITDA is $650–$730 million, with 2028 adjusted EBITDA projected at $760–$840 million, signaling a financial inflection point.
• 2027 revenue is expected to grow in the low single digits, driven by normalized channels and new product registrations, while 2028 growth is expected to accelerate with full-year benefits from new manufacturing footprints and new active ingredient launches.
• Management expects the commercial actions to materially reduce inventory volatility, simplify pricing, and improve competitiveness against generic alternatives.
• FCF for 2027 is expected to be potentially break-even before restructuring costs, though formal guidance will be provided in February 2027.
• Strategic divestitures of the India business (expected December 1 close) and a Delaware site sale are anticipated to close in Q4 2026, generating additional cash proceeds.

Business Segments and Product Lines:

• North America: Transitioned from a high gross price/high rebate model to a lower gross price/close-to-net model to alleviate customer inventory constraints; a $500 million non-cash charge reflects this structural change.
• South America (Brazil/Argentina) & US/Canada: Reduced prices on select high-priced products held in channel inventory to facilitate downstream movement; this $175 million impact is expected to reduce future cash collections via credit notes.
• Product Pipeline: New active ingredients are driving growth, including Fluent (food-up with six new country registrations), Isoflex, and Blue Elix; Remisoxafen expected to launch in 2028.
• R&D Strategy: Commitment to maintain current R&D spending levels to support new technology development, with a potential shift toward partnership models for future single-molecule development to reduce costs and increase speed.
• Manufacturing: Ongoing footprint redesign is expected to lower costs for core brands by shifting sales to low-cost sites, with full benefits realized in 2028.
• India Business: Divestiture to Crystal Crop remains on track for December 2026 closing, with an expected transaction value of approximately $260 million plus working capital extraction.

Market and Competitive Landscape:

• Demand Conditions: Q3 performance was pressured by sharp reductions in customer replenishment orders as channels sought to minimize inventory values amid high financing costs and supply uncertainty.
• Competitive Pressure: Increased competition from generic alternatives following IP expirations necessitated strategic pricing actions and the commercial restructuring.
• Market Trends: High single-digit price declines are expected in Q4 due to patent expirations; demand uncertainty persists due to potential El Niño impacts and geopolitical disruptions (Middle East, Brazil election).
• Inventory Dynamics: Customers are holding record low inventory levels, creating a constraint on FMC's ability to replenish orders due to the legacy pricing model's high gross-to-net spread.

Risks and Challenges:

• Inventory Overhang: High-value legacy inventory held by customers at prices above current market levels has delayed product movement to growers, constraining future sales.
• Market Volatility: Potential El Niño weather events and geopolitical tensions (Middle East, Brazil) pose risks to volume and pricing stability.
• Cash Flow Constraints: The transition to the new business model and channel pricing adjustments create a temporary drag on free cash flow and future collections.
• Execution Risk: The success of the 2027/2028 recovery relies on the timely execution of commercial actions and manufacturing footprint changes.
• Tax Implications: Significant non-cash adjustments to deferred tax assets and intangible asset impairments (specifically related to the Ranaxapir business) impacted reported earnings.

Management Commentary and Tone:

• Tone: Management acknowledged the challenging quarter but framed the $672 million charges as a necessary, "comprehensive" reset to address a critical commercial constraint, projecting a return to growth in 2027.
• Confidence: CEO Pierre Brondeau expressed strong confidence that the actions are "vital" to returning the company to growth, emphasizing that future performance will be driven by top-line expansion rather than further cost cutting.
• Strategic Shift: Management indicated that future SG&A may need to be revisited if top-line growth targets are not met, but current focus is on enabling growth through the new pricing model and new technologies.
• Stakeholder Engagement: CEO noted that initial customer feedback regarding the new pricing model and inventory adjustments has been "very positive," suggesting the actions are being well-received.
• Liquidity Focus: CFO Andrew Sandefur emphasized a priority on liquidity during the transition, planning to largely self-finance the seasonal working capital build in H1 2027.

Analyst Questions and Answers:

• Cash Flow Mechanics: Clarified that the $500 million North America pricing charge is non-cash and cash-flow neutral over the crop season, while the $175 million channel inventory adjustment will likely be a cash headwind over a 4–6 quarter period via credit notes.
• Cost Structure: Management confirmed SG&A dollars have remained relatively flat for years, with the increased SG&A-to-sales ratio resulting from declining revenue; future efficiency depends on top-line growth.
• India Divestiture: Confirmed the carrying value of the India business is $260 million, with the total transaction value (including working capital) expected to remain around the $400 million mark.
• FX Impacts: Brazilian Real volatility following the recent election is not expected to significantly impact Q4 guidance, as planning continues to use pre-election rates; modest FX headwinds are anticipated for full-year 2026 EBITDA.
• 2027 Growth Drivers: Analysts were briefed that 2027 core business growth will be net positive for both volume and price, driven by the normalization of the channel and the removal of legacy pricing distortions.
• FCF Bridge: The reduction in 2026 FCF guidance is attributed to Q3 underperformance, lower Q4 EBITDA expectations, reduced collections from lower Q3 sales, and timing impacts of the new pricing model.

Other Key Points:

• Investment: Tessenderlo Group completed a $403 million equity investment in September 2026, now owning approximately 20% of FMC; Luc Tac (CEO of Tessenderlo) has joined the FMC Board.
• Restructuring: 2026 restructuring spending is expected to be approximately $180 million in cash, with significant costs already incurred in Q3; 2027 spending is expected to be lower but still meaningful.
• Non-GAAP Measures: The earnings release and call referenced adjusted EPS, adjusted EBITDA, and free cash flow, with reconciliations available on the IR website.
• Forward-Looking Statements: Management reiterated that actual results may vary due to risks and uncertainties outlined in SEC filings, particularly regarding the execution of commercial actions and market conditions.